In focus
Latest feed
Merck’s First Oral PCSK9 Inhibitor Faces Real‑World Hurdles
Rare‑Disease Biotechs Push Back on Trump’s Price‑Cut Push While PBMs Slip Around State Laws
Iowa Medicaid Audit Exposes $100 Million PBM Overcharges and Creative Spread‑Pricing Workarounds
The GLP-1 Revolution: A Budgetary Tightrope for Medicare and Medicaid
